Lead
Americans born in 2024 can expect to live, on average, to age 79, a rise of more than half a year from 2023, according to a National Center for Health Statistics report released Thursday. The new figure marks the highest U.S. life expectancy since the federal government began tracking the metric in 1900 and exceeds the previous peak reached in 2019. Health officials say the rebound reflects sustained declines in deaths from drug overdoses and COVID-19. Experts caution, however, that deep geographic and racial disparities remain and that the United States still trails many other wealthy nations.
Key Takeaways
- Life expectancy for U.S. births in 2024 rose to 79.0 years, the highest on record since 1900, up more than 0.5 years from 2023.
- The NCHS identifies two primary drivers of the rebound: a continued fall in drug overdose deaths and a drop in COVID-19 mortality.
- Nearly 80,000 Americans died from drug overdoses in 2024; more than 30,000 died from COVID-19 in the same year.
- COVID-19 fell out of the top 10 causes of death in 2024 and ranked No. 15, compared with being the third leading cause at the pandemic’s peak.
- Despite the national gain, substantial variation persists across states, counties and racial and ethnic groups, leaving many communities with much lower life expectancy.
- Compared with peer countries such as Australia, Spain and Japan, the U.S. remains below the upper range of developed-country life expectancy, where many exceed 80 years.
- Officials reported preliminary 2025 indicators look favorable but said it is too early to confirm a sustained trend.
Background
U.S. life expectancy fell sharply during 2020–2022 as the COVID-19 pandemic and a surge in drug overdose deaths pushed mortality upward. The 2019 level—long regarded as a recent high—was eclipsed in 2024, marking a recovery that public-health statisticians say began as pandemic-era mortality declined and overdose deaths started to retreat. The NCHS, part of the Centers for Disease Control and Prevention, compiles national vital statistics each year to produce the life-expectancy estimate used by policymakers and researchers.
Drug overdose mortality climbed over roughly a decade before peaking in recent years, driven in part by synthetic opioids and polysubstance use. COVID-19 accounted for tens of thousands of deaths in 2020–2022; as population immunity and treatments expanded, COVID-related deaths declined. Still, pre-pandemic challenges—high maternal and infant mortality and rising suicide in certain groups—remained part of the American mortality landscape.
Main Event
On Thursday the NCHS released its 2024 life-expectancy estimate showing an average of 79 years for those born that year. Agency officials, including Robert Anderson, chief of the statistical analysis and surveillance branch in NCHS’s vital statistics division, attributed the gain mainly to fewer deaths from drug overdoses and from COVID-19 compared with recent years. Anderson described the rise as evidence the nation is moving back toward a post-pandemic baseline.
The NCHS data show nearly 80,000 overdose deaths in 2024 and over 30,000 COVID deaths. While both causes remain significant contributors to U.S. mortality, their declines relative to recent peaks accounted for most of the life-expectancy improvement. COVID’s position among leading causes dropped to No. 15 in 2024 after having been the third leading cause at the pandemic height, according to the report.
Although the national average increased, the NCHS and outside experts highlighted strong subnational differences. Some states and many counties still report life expectancies well below the national average, reflecting local variations in healthcare access, socioeconomic conditions, substance-use patterns and other determinants of health. Public-health professionals emphasize that an overall national gain does not erase these uneven outcomes.
Analysis & Implications
The increase to 79 years carries practical and policy significance. On the one hand, a rise in life expectancy can ease pressure on planners worried about immediate post-pandemic mortality shocks and can signal improved control of particular causes of death. It may also indicate effective deployment of vaccines, therapeutics and harm-reduction measures that helped lower COVID and overdose mortality in 2023–2024.
On the other hand, the U.S. remains behind many high-income peers; most developed countries report life expectancies exceeding 80 years. That gap suggests structural differences—health-care coverage, social safety nets, environmental and occupational risks, and long-term investments in prevention—that influence population longevity beyond short-term declines in specific causes.
Persistent disparities mean that gains are not evenly shared. Communities with higher poverty, limited health-care access, or concentrated substance-use disorders may see little improvement or even worsening outcomes. Policymakers face a choice: build on recent momentum with targeted public-health interventions, or risk backsliding if underlying drivers—economic inequality, limited access to care, and regulatory settings—are not addressed.
Finally, projections for future improvement hinge on policy, funding and public behavior. Early 2025 indicators reported by NCHS officials are encouraging, but analysts warn that the direction of health policy and resource allocation can accelerate or reverse progress over the medium term.
Comparison & Data
| Metric | 2024 (value) |
|---|---|
| Life expectancy at birth | 79.0 years |
| Estimated drug overdose deaths | ~80,000 |
| Estimated COVID-19 deaths | >30,000 |
| COVID rank among causes of death (2024) | No. 15 |
The table highlights the central numerical drivers underpinning the life-expectancy increase. While the national average reached a record high, cross-jurisdictional comparisons show a range of local outcomes: some states and counties remain below the national figure by multiple years of life expectancy. Internationally, most wealthy countries report life expectancies above 80 years, underscoring a remaining U.S. shortfall.
Reactions & Quotes
Officials and experts framed the news as cautiously positive while stressing ongoing challenges.
“We seem to have rebounded from the pandemic. This may just signal that we’re back to some semblance of normal post-pandemic.”
Robert Anderson, NCHS (CDC official)
Anderson emphasized the numerical role of reduced COVID and overdose mortality in the increase.
“It’s very encouraging to see that mortality is declining and life expectancy is increasing in the United States, but we still see very high mortality from drugs, suicide, infant and maternal mortality.”
Ali Mokdad, University of Washington (epidemiologist)
Mokdad urged that the gain not obscure persistent and preventable causes of death concentrated in certain populations.
“We worry that the crisis conditions that we were already seeing before the pandemic will continue to deepen unless we adopt policies that really would make America healthy again.”
Steven Woolf, Virginia Commonwealth University (public-health scholar)
A spokesperson for the Department of Health and Human Services highlighted current administration priorities on chronic disease prevention and nutrition initiatives as part of its response.
Unconfirmed
- Preliminary 2025 figures: NCHS officials describe early 2025 indicators as promising, but full-year data are not yet available and trends could change.
- Long-term policy impacts: Claims that specific administration policies will definitively reverse or accelerate life-expectancy trends are projections and depend on future regulatory, funding and health-care developments.
- Effect size of particular initiatives: Departmental statements about programs such as the MAHA Strategy and the 2025–2030 Dietary Guidelines assert benefits; independent evaluation will be necessary to confirm population-level impact.
Bottom Line
The NCHS finding that life expectancy rose to 79 years in 2024 is a meaningful reversal of earlier declines driven by COVID-19 and drug overdoses. The improvement largely reflects reductions in those two high-burden causes of death, and it signals progress in the nation’s immediate recovery from the pandemic.
However, the headline gain masks deep and persistent disparities across places and population groups, and the United States still falls short of many peer countries on longevity. Whether the 2024 increase marks the start of sustained improvement will depend on policy choices, investments in prevention and health equity, and continued attention to substance-use and mental-health crises.